Atopic Dermatitis

Audrey Dean’s case highlights the significance of tailoring treatments to individual patient needs, acknowledging that what works for one person might not work for another.

Connect Biopharma announced positive long-term data from its China pivotal trial.

Patients with AD and a comorbid allergic condition achieved the same efficacy endpoints as patients without allergic conditions in a study.

From the November cover: Raj Chovatiya, MD, PhD, and Lawrence Eichenfield, MD, shared their insights and key treatment pearls into atopic dermatitis management for adults and children.

Jared Gollob, MD, Chief Medical Officer of Kymera Therapeutics, spoke with Dermatology Times to discuss these trial results.

Germany will be the first country where lebrikizumab will be available for prescription, with a subsequent rollout across European countries throughout 2024.

What are some of the challenges and triumphs in using biologics for atopic dermatitis? Abby L. Allen, RN, NP, shares insights at the American College of Allergy, Asthma and Immunology 2023 Annual Scientific Meeting.

Research at the American College of Allergy, Asthma and Immunology (ACAAI) 2023 Annual Scientific Meeting discusses the impact of an educational program on improving care.

Ruchi Gupta, MD, MPH, shares tips for supporting a successful transition to college for patients with atopic dermatitis.

A new study presented at this year’s American College of Allergy, Asthma and Immunology Annual Scientific Meeting highlights the need for mental health support in patients with atopic dermatitis.

The guidelines update AAD’s 2014 recommendations for the management of AD with phototherapy and systemic therapies.

Study authors urge clinicians to screen adult patients with AD for cognitive dysfunction.

Polyphenols, found in certain foods, have antioxidant and anti-inflammatory properties may help modulate immune responses, offering potential adjunctive therapy for atopic dermatitis, psoriasis, and chronic urticaria.

Delgocitinib is first-in-class pan-Janus kinase inhibitor.

The results from this 5-year open-label extension trial affirm the safety of dupilumab in adults with moderate to severe AD.

Almost 80% of patients in an extension study maintained clear or almost clear skin, and 90% of patients saw continued improvements in itch.

Investigators said that additional, larger studies are needed to assess the safety of live attenuated vaccine administration for pediatric AD patients being treated with dupilumab.

The most common conditions or concerns patients reported having that may influence their selection of a JAK inhibitor included an increased risk of MACE and an age above 65 years.

Little is known about the ways primary care physicians should treat or manage atopic dermatitis in their patients, according to the review.

Lisa Sanglay, FNP, and Lauren Miller, PA-C, interviewed a patient at IDS 2023 who used to have debilitating atopic dermatitis before seeing Sanglay for help and who prescribed upadacitinib.

Skin clearance, itch relief, and reduced severity of atopic dermatitis were sustained with monthly maintenance dosing.

With October being National Eczema Awareness Month, there is robust research about the power of the microbiome and eczema.

While blue light irradiation was efficacious in reducing itch and IL-31 levels, it did not reduce any of the objective measures of AD.

The expanded study data correlates with the safety and efficacy of ruxolitinib cream in patients with atopic dermatitis.

Sanofi’s phase 3 program for amlitelimab in atopic dermatitis will start in early 2024.

Almirall presented new data on lebrikizumab at EADV related to clinical improvements and clinically-meaningful treatment responses among patients with atopic dermatitis.

This month's cover feature delves into the new applications and use of AI in dermatology and considers how AI can support clinicians rather than hinder them.

New data from ADORING 1 and ADORING 2 show a rapid reduction in pruritus relief as early as 24 hours after the first application.

Dermatologist Diego Ruiz Dasilva, MD, FAAD, and a patient with atopic dermatitis discuss the patient journey from initial symptoms to diagnosis to treatment selection.

The data presents compelling evidence for the sustained efficacy and safety of the oral JAK1 inhibitor in the treatment of moderate to severe atopic dermatitis over an extended 140-week period.